Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir-Reference-Cited by-同舟云学术

Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir

Published:2021-05-18 Issue:6 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Terrier Jean¹²^ORCID,Zanella Marie-Céline³^ORCID,Masouridi-Levrat Stavroula⁴,Kronig Ilona³,Chalandon Yves⁴,Vernaz Nathalie⁵,Van Delden Christian³,Papanicolaou Genovefa⁶,Neofytos Dionysios³^ORCID

Affiliation:

1. Division of Clinical Pharmacology and Toxicology Service, Geneva University Hospitals, Geneva, Switzerland

2. Division of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland

3. Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland

4. Hematology Division, Oncology Department, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland

5. Medical Directorate, Finance Directorate, Geneva University Hospitals, University of Geneva, Geneva, Switzerland

6. Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Abstract

We sought in this case-control retrospective study to compare posaconazole and isavuconazole (PCZ and IVC, respectively) plasma trough concentration ( C trough ) levels in high-risk allogeneic hematopoietic cell transplant (HCT) recipients who received letermovir (LET) or not. PCZ/IVC C trough levels were not found to be significantly different between cases and controls, as they were 1.31 mg/liter (median) (interquartile range [IQR], 0.90) versus 1.36 mg/liter (IQR, 1.16) ( P = 0.31) and 3.20 mg/liter (IQR, 2.40) versus 2.35 mg/liter (IQR, 1.50) ( P = 0.17), respectively.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00274-21

Reference20 articles.

1. Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease

2. Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

3. Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism

4. Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole

5. Posaconazole: A Broad-Spectrum Triazole Antifungal Agent

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Isavuconazole induces neurodevelopment defects and motor behaviour impairment in zebrafish embryos;2023-12-13

2. Comparing the Real-World Use of Isavuconazole to Other Anti-Fungal Therapy for Invasive Fungal Infections in Patients with and without Underlying Disparities: A Multi-Center Retrospective Study;Journal of Fungi;2023-01-27

3. Cytomegalovirus Therapy: Role of Letermovir in Prophylaxis and Treatment in Transplant Recipients;Annual Review of Medicine;2023-01-27

4. Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients;Antimicrobial Agents and Chemotherapy;2022-08-16

5. American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation;Transplantation and Cellular Therapy;2021-09